Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Reported Tuberculosis in the United States, 2020					minus icon
                Table of Contents
			National DataState & Local DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBGenotype ClustersEstimates of Recent Transmission					Related Pages
					Return to Main Menu
TB Treatment and Case OutcomesOn This Page
			HighlightsTB TreatmentCase OutcomesData TablesHighlightsSuccessful completion of TB treatment for persons with TB disease is a major performance indicator for TB programs.
Data collected by date and reason therapy was stopped (e.g., the patient completed therapy or the patient died) were used to calculate completion of therapy percentages. Cases of TB disease were stratified by the indicated length of therapy, based on American Thoracic Society, CDC, and Infectious Diseases Society of America treatment guidelinespdf icon in effect during the period covered, the patient’s initial drug-susceptibility test results, age, and disease site.TB TreatmentEffective TB treatment for TB disease includes providing multiple anti-TB drugs given over a sufficient period of time to prevent development of drug resistance, minimize the risk of transmission to others, and ultimately, cure the patient of TB disease.
The most common initial treatment regimen for drug-susceptible TB disease, and in situations where drug-susceptibility is unknown, includes isoniazid, H; rifampin, R; pyrazinamide, Z; and ethambutol, E (HRZE).
Percentage of TB Cases,* by Initial Drug Regimen, United States, 2020 (N=7,174)resize iconView LargerClosePercentage of TB Cases,* by Initial Drug Regimen, United States, 2020 (N=7,174)download iconDownload Image[PNG]
Among persons alive at diagnosis with initial drug regimen information available in 2020,
83.3% began treatment with HRZE,
10.7% began treatment with a four-drug regimen other than HRZE, and
6.0% were not on a four-drug regimen.*Source: Treatment and Outcomes Among TB Cases: 1993–2020*
Successful completion of TB therapy for TB disease is important to prevent recurrence of TB disease and drug resistance.
Percentage of TB Cases by Completion of TB Therapy, United States, 1993–2018*resize iconView LargerClosePercentage of TB Cases by Completion of TB Therapy, United States, 1993–2018*download iconDownload Image[PNG]
The national goal for treatment completion is that, for patients with newly diagnosed TB disease for whom ≤12 months of treatment is indicated, 95% complete treatment within 12 months.
Although the percentage of eligible patients completing therapy in 1 year has risen since 1993 from 63.4% to 89.1% in 2018, the nation is still short of the 95% goal, and the percentage has been relatively level since 2009.Case OutcomesPercentage of TB Cases by Status and Cause of Death, United States, 2018* (N=9,006)resize iconView LargerClosePercentage of TB Cases by Status and Cause of Death, United States, 2018* (N=9,006)download iconDownload Image[PNG]
In 2018, the most recent year for which complete data are available, among persons with TB disease, 801 (8.9%) died (Deaths Among TB Cases: 2010–2018).
There were 197 patients who were dead at the time of TB diagnosis and 604 patients who died during treatment.
Out of the 8.9% who died, slightly more than 35% were attributed to TB disease.
The percentage who died among persons with TB disease has remained consistent with previous years.Learn more in the Executive Commentary.Data TablesOpen All Close All
TB TreatmentTreatment and Outcomes Among TB Cases: 1993–2020
TB by Initial Drug Regimen: Reporting Areas, 2020
Drug Resistance: Reporting Areas, 2020
Directly Observed Therapy (DOT): Reporting Areas, 2018
Persons Completing Therapy for Whom Therapy Was Indicated for ≤1 Year: Reporting Areas, 2014–2018Case OutcomesReason TB Therapy Was Stopped: 1993–2018
Sputum Culture Conversion: 2010–2018
Reason TB Therapy Was Stopped: Reporting Areas, 2018
Reason TB Therapy Was Extended: Reporting Areas, 2018
Completion of TB Therapy (COT): Reporting Areas, 2018Top of Page
					PrevDemographics
			NextDrug-Resistant TB
							
					
						Page last reviewed:  October 18, 2021					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue